Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Predicting risk of fracture in MGUS patients

Jad Sfeir • 14 Sep 2019
IMW 2019
Multiple Myeloma

Dr Jad Sfeir MD, of the Mayo Clinic College of Medicine, Rochester, MN, discusses the significance of monoclonal gammopathy of undetermined significance (MGUS), and why improved clinical availability of measures of bone micro-architecture would be invaluable in the better estimation of fracture risk. Discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals